IMV VE/BAIIA
Quel est le VE/BAIIA de IMV?
Le VE/BAIIA de IMV, Inc. est N/A
Quelle est la définition de VE/BAIIA?
VE/BAIIA est la valeur de l’entreprise divisée par le bénéfice avant intérêts, impôts, dépréciations et amortissements. Il s'agit d'une mesure du coût d'une action et est plus souvent valable pour des comparaisons entre sociétés que le ratio cours / bénéfice. Il mesure le prix (sous forme de valeur d'entreprise) qu'un investisseur paie au profit des flux de trésorerie de l'entreprise (sous forme de BAIIA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
VE/BAIIA des entreprises dans Health Care secteur sur TSX par rapport à IMV
Que fait IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Entreprises avec ve/baiia similaire à IMV
- Primo Nutraceuticals a VE/BAIIA de N/A
- Killi a VE/BAIIA de N/A
- Nautilus Inc a VE/BAIIA de N/A
- CPP Plc a VE/BAIIA de N/A
- Lee Hing Development a VE/BAIIA de N/A
- Blockmate Ventures a VE/BAIIA de N/A
- IMV a VE/BAIIA de N/A
- Great Atlantic Resources a VE/BAIIA de N/A
- Paringa Resources a VE/BAIIA de N/A
- Virios Therapeutics a VE/BAIIA de N/A
- Asimilar Plc a VE/BAIIA de N/A
- Sanbase a VE/BAIIA de N/A
- Deep-South Resources a VE/BAIIA de N/A